Products
 
Jintrolong
Strengths
Features
How to use
Indications
Follitropin
Strengths
Features
Indication
Jintropin AQ
Strengths
Features
Indications
Advantages
User guide to Jintropin AQ
Jintropin for Injection
Strengths
Features
Indications
User guide to Jintropin
Genfulin
Strengths
Features
Indications
How to use
Filgrastim
Strengths
Features
Indications
How to use
Filgrastim PFS
Strengths
Features
Indications
How to use
Octreotide
Strengths
Features
Indications
How to use
PEG products
Linear PEG Derivatives
Branched PEG Derivatives
Multi-Arm PEG Derivatives
PEG Raw Materials
New Products coming soon
Thymosin
 
You are here: Home >> Products >> Octreotide
 
    

Jintrotide® (Octreotide acetate for injection) is a synthetic octapeptide derivative of naturally occurring somatostatin with similar pharmacological effects and longer duration of action. Jintrotide® is formulated as white powder. It inhibits the secretion of
growth hormone (GH) and peptides from the gastroenteropancreatic (GEP) endocrine system.

Strengths:
          *   0.1 mg/vial
          *   0.3 mg / vial

Features:
          *   Synthetic octapeptide
           *   An inhibitor of growth hormone, glucagon and insulin
           *   Launched in 2004
           *   More than 7 years of good safety record on the market

Indications:
          *   Emergency treatment of bleeding esophageal varices in patients with cirrhosis of the liver, combined with specific
treatments (such as endoscopy hardners).
          *   Prevent the occurrence of the complications associated with the pancreatic surgical.
          *   Remit symptoms and vital signs associated with gastro-intestinal endocrine tumors. It has been proved that this drug is effective for the following tumors:
              - carcinoid tumors with features of the carcinoid syndrome
              - VIPomas (vasoactive intestinal peptide tumors)
              - Glucagonomas
                 The effectiveness rate is about 50% for the following tumors(with limited case load being treated with this drug):
               - Gastrinomas / Zollinger-Ellison syndrome
               - Insulinomas
               - GRFomas (growth hormone releasing factor tumors)
          Reduce the levels of growth hormone (GH) and somatomedin C in acromegaly patients in whom surgical resection,
pituitary irradiation and dopamine receptor agonist treatment is ineffective, whom are not suitable for or cannot be treated with surgical resection, or whom in interim period with inadequate response to pituitary irradiation.

How to use:
          *   Gastro-esophageal varices bleeding: 0.025 mg/hour by intravenous drip for at most 5 days. The injection can be
diluted with physiological saline or glucose injection.
          *   Complications associated with pancreatic surgery: Administer 0.1 mg three times daily for a period of consecutive 7
days, the initial dosage should be administered at least one hour prior to the surgery.
          *   Gastro-entero-pancreatic endocrine tumors: Start the treatment at a dosage of 0.05 mg by subcutaneous
administration twice daily, gradually increase the dosage to 0.2 mg three times daily according to the assess of the tolerance and effectiveness.
          *   Acromegaly: dosage may be initiated at 0.05-0.1 mg by subcutaneous administration every 8 hours. The dose should be adjusted under the monthly evaluation of growth hormone (GH) concentration, clinical reactions and tolerance. The dose
most commonly found to be effective is 0.2-0.3 mg daily, maximum dose is 1.5 mg per day. The dose
may be reduced after dosing for a few months according to the reevaluation of the growth hormone (GH) level. This drug
should be withdrawn for approximately 1 month from patients if growth hormone level is decreased or symptoms are not
improved.

 
 

吉ICP备14004136号-1               GeneScience Pharmaceuticals Co., Ltd. (GenSci)  All Rights Reserved